<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03850626</url>
  </required_header>
  <id_info>
    <org_study_id>cSMS-2018</org_study_id>
    <nct_id>NCT03850626</nct_id>
  </id_info>
  <brief_title>Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients</brief_title>
  <official_title>Validierung Des cSMS in Patienten Mit Allergischer Rhinokonjunktivitis (Baum- Und Gräserpollen, Hausstaubmilben). - Eine NIS Bei Patienten, Die Depigoid® Als Spezifische Immuntherapie Erhalten</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leti Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Leti Pharma GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CSMS was defined by the European Academy of Allergy and Immunology Taskforce as a
      standardised tool to assess clinical effects of allergen-specific immunotherapy (AIT). The
      aim of this study is to validate the CSMS as a tool to assess the clinical effects of
      Depigoid AIT, so that the CSMS can be used in future studies as a primary endpoint as well as
      a comparative parameter.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 20% of the general public suffer from seasonal or perennial allergic
      rhinoconjunctivitis. The only available curative therapy is AIT. The effectiveness of AIT was
      demonstrated in numerous randomized clinical trials but comparability is difficult because of
      different primary and secondary endpoints.

      To validate the CSMS, adolescent (≥ 12 years) and adult patients will be observed who are
      allergic to house dust mites (HDM), tree or grass pollen and who were treated with Depigoid.
      Depigoid is a registered (for tree and grass pollen) respective authorized (for HDM)
      suspension for injection for the treatment of immediate type allergic diseases. Depigoid
      contains depigmented and chemically modified allergen extracts, so called allergoids, derived
      from grass pollen, tree pollen or HDM.

      Allergy symptoms will be documented over a time period of two years: Either for two
      consecutive allergy seasons (for tree and grass pollen allergic patients) or for two
      consecutive exposure periods (September-December) for HDM allergic patients. The symptoms (4
      nasal and 2 ocular symptoms) and allergy medication intake will be documented on a daily
      basis either using the CSMS questionnaire or the especially developed electronic CSMS+ diary
      application.

      Already validated and established questionnaires will be used to validate the CSMS with
      regard to Quality of Life (QoL) and symptom control: the Rhinoconjunctivitis Quality of Life
      Questionnaire (RQLQ), Adolescent RQLQ (AdolRQLQ, for patients aged 12-17 years), Asthma
      Quality of Life Questionnaire (AQLQ) and AQLQ for patients aged 12 years and older (AQLQ+12),
      the Asthma Control Test (ACT), Rhinitis Control Assessment Test (RCAT) and the Visual
      Analogue Scale (VAS).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2018</start_date>
  <completion_date type="Anticipated">August 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>cSMS</measure>
    <time_frame>after up to 60 days during allergen exposure period (=pollen season resp. allergen season) in 2 consecutive years</time_frame>
    <description>Combined Symptom and Medication Score</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Allergic Rhinoconjunctivitis</condition>
  <condition>Allergic Asthma</condition>
  <arm_group>
    <arm_group_label>Immunotherapy Trees</arm_group_label>
    <description>Patients allergic to tree pollen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immunotherapy Grass</arm_group_label>
    <description>Patients allergic to grass pollen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immunotherapy Mites</arm_group_label>
    <description>Patients allergic to HDM</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immunotherapy</intervention_name>
    <description>subcutaneous injection</description>
    <arm_group_label>Immunotherapy Grass</arm_group_label>
    <arm_group_label>Immunotherapy Mites</arm_group_label>
    <arm_group_label>Immunotherapy Trees</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        adults and adolescents suffering from allergic diseases (rhinitis, rhinoconjunctivitis,
        with or without concomitant asthma)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Indication of an allergen-specific immunotherapy with Depigoid

        Exclusion Criteria:

        - exclusion criteria according to the SmPC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angelika Sager, Dr.med.</last_name>
    <role>Study Director</role>
    <affiliation>Medical Department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Mueller, Dr.rer.nat.</last_name>
    <phone>+4989121400</phone>
    <phone_ext>268</phone_ext>
    <email>t.mueller@leti.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eva-Cornelia Ticinelli</last_name>
    <phone>+49230220286</phone>
    <phone_ext>142</phone_ext>
    <email>ticinelli@leti.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dr. med Andrea Kienle-Gogolok</name>
      <address>
        <city>Bad Schönborn</city>
        <zip>76869</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Kienle-Gogolok, Dr. med.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 18, 2019</study_first_submitted>
  <study_first_submitted_qc>February 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2019</study_first_posted>
  <last_update_submitted>February 22, 2019</last_update_submitted>
  <last_update_submitted_qc>February 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergy</keyword>
  <keyword>Rhinoconjuctivitis</keyword>
  <keyword>Combined Symptom and Medication Score</keyword>
  <keyword>Allergic Asthma</keyword>
  <keyword>Pollen</keyword>
  <keyword>Mites</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

